SG11201405098PA - Self-preserved oil dispersions comprising boric - Google Patents
Self-preserved oil dispersions comprising boricInfo
- Publication number
- SG11201405098PA SG11201405098PA SG11201405098PA SG11201405098PA SG11201405098PA SG 11201405098P A SG11201405098P A SG 11201405098PA SG 11201405098P A SG11201405098P A SG 11201405098PA SG 11201405098P A SG11201405098P A SG 11201405098PA SG 11201405098P A SG11201405098P A SG 11201405098PA
- Authority
- SG
- Singapore
- Prior art keywords
- boric
- self
- oil dispersions
- preserved oil
- preserved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Colloid Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602369P | 2012-02-23 | 2012-02-23 | |
| EP12156652.5A EP2630952A1 (en) | 2012-02-23 | 2012-02-23 | Self-preserved oil dispersions comprising boric acid |
| PCT/EP2013/053556 WO2013124415A1 (en) | 2012-02-23 | 2013-02-22 | Self-preserved oil dispersions comprising boric |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405098PA true SG11201405098PA (en) | 2014-09-26 |
Family
ID=45656502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405098PA SG11201405098PA (en) | 2012-02-23 | 2013-02-22 | Self-preserved oil dispersions comprising boric |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9682147B2 (en) |
| EP (2) | EP2630952A1 (en) |
| JP (2) | JP6231499B2 (en) |
| KR (1) | KR20140124405A (en) |
| CN (1) | CN104220048A (en) |
| AU (1) | AU2013224043B2 (en) |
| CA (1) | CA2862932A1 (en) |
| EA (1) | EA201400869A1 (en) |
| HK (2) | HK1203154A1 (en) |
| IN (1) | IN2014DN06853A (en) |
| MX (1) | MX2014010005A (en) |
| MY (1) | MY169504A (en) |
| NZ (1) | NZ627861A (en) |
| PH (1) | PH12014501906A1 (en) |
| SG (1) | SG11201405098PA (en) |
| TW (1) | TWI564032B (en) |
| UA (1) | UA112669C2 (en) |
| WO (1) | WO2013124415A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2782584T (en) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP2017516768A (en) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | Natural combination hormone replacement therapy and therapy |
| US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
| AU2016222902A1 (en) * | 2015-02-24 | 2017-08-31 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| US10004683B2 (en) | 2015-06-18 | 2018-06-26 | Common Pharma, Inc. | Antimicrobial formulations |
| EP3310363A4 (en) * | 2015-06-18 | 2019-02-13 | Common Pharma, Inc | Antimicrobial formulations |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| EP3328440A4 (en) * | 2015-07-28 | 2019-01-16 | Otonomy, Inc. | Treatment using truncated trk b and trk c antagonists |
| KR20180126582A (en) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| PL3231417T3 (en) * | 2016-04-15 | 2019-05-31 | Dr Gerhard Mann Chem Pharm Fabrik Gmbh | Storage stable, ophthalmic compound |
| US9821510B2 (en) * | 2016-04-18 | 2017-11-21 | Xerox Corporation | Using depth in three-dimensional object printing to form colors that change with viewing and illumination angles |
| BE1024559B1 (en) * | 2017-02-21 | 2018-04-05 | Purna Pharmaceuticals Nv | Process for making a sprayable emulsion comprising a corticosteroid, an aminoglycoside and an acid |
| CN107019669B (en) * | 2017-04-13 | 2020-01-21 | 山东天音生物科技有限公司 | Zeaxanthin nanosuspension and preparation method thereof |
| EP3624773A4 (en) | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| EP3709968B1 (en) * | 2017-11-14 | 2023-08-23 | ProFem GmbH | Emulsions for the treatment of vaginal infections |
| SG11202010472XA (en) | 2018-04-24 | 2020-11-27 | Allergan Inc | Use of pilocarpine hydrochloride for the treatment of ocular conditions |
| MY198184A (en) | 2018-09-21 | 2023-08-09 | Petroliam Nasional Berhad | Ionic liquids formulation as an environmentally friendly oil dispersant |
| CN108853016A (en) * | 2018-09-26 | 2018-11-23 | 广州大光制药有限公司 | A kind of ophthalmic solution sodium eye drops and preparation method thereof |
| US20230049050A1 (en) * | 2019-12-18 | 2023-02-16 | National Research Council Of Canada | Emulsions of bioactive lipophilic compounds including oils |
| GR1010012B (en) * | 2020-05-12 | 2021-05-27 | Φαρματεν Α.Β.Ε.Ε. | Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine |
| TWI819317B (en) * | 2021-06-07 | 2023-10-21 | 溫士頓醫藥股份有限公司 | Ophthalmic nanoemulsion composition containing prostaglandin derivatives |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW274516B (en) | 1993-11-12 | 1996-04-21 | Ciba Geigy Ag | |
| ATE252369T1 (en) * | 1996-08-09 | 2003-11-15 | Alcon Mfg Ltd | PRESERVATION SYSTEMS FOR MEDICINAL PRODUCTS CONTAINING CYCLODEXTRINS |
| US6379688B2 (en) * | 1997-02-28 | 2002-04-30 | Senju Pharmaceutical Co., Ltd. | Preservative for emulsion and emulsion containing same |
| JP4221073B2 (en) * | 1997-02-28 | 2009-02-12 | 千寿製薬株式会社 | Emulsion preservative and emulsion |
| US6166012A (en) | 1999-07-30 | 2000-12-26 | Allergan Sales, Inc. | Antibiotic compositions and method for using same |
| DE19954516A1 (en) * | 1999-11-12 | 2001-05-17 | Boehringer Ingelheim Int | Solutions containing epinastine |
| US6528070B1 (en) * | 2000-09-15 | 2003-03-04 | Stepan Company | Emulsion comprising a ternary surfactant blend of cationic, anionic, and bridging surfactants, oil and water, and methods of preparing same |
| AU2002350207A1 (en) * | 2001-11-19 | 2003-06-10 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
| US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
| US20060233739A1 (en) * | 2003-11-24 | 2006-10-19 | Thornfeldt Carl R | Treatment of mucocutaneous disorders through reversing chronic imflammation and barrier disruption |
| US20060141059A1 (en) | 2004-12-27 | 2006-06-29 | Alcon, Inc. | Self-preserved ophthalmic pharmaceutical compositions containing tobramycin |
| TWI394564B (en) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | Self-preserved aqueous pharmaceutical compositions |
| US20100021561A1 (en) | 2006-09-21 | 2010-01-28 | Chowhan Masood A | Self-preserved aqueous pharmaceutical compositions |
| EP2066300B2 (en) * | 2006-09-28 | 2019-01-23 | Novartis Ag | Self-preserved aqueous pharmaceutical compositions |
| EP2197449A4 (en) * | 2007-10-16 | 2013-10-09 | Sun Pharma Advanced Res Co Ltd | Novel ophthalmic compositions |
| US8669241B2 (en) | 2008-12-02 | 2014-03-11 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition |
| EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| TWI478730B (en) * | 2009-12-03 | 2015-04-01 | Alcon Res Ltd | Ophthalmic emulsion |
| JP6093701B2 (en) * | 2011-07-08 | 2017-03-08 | ロート製薬株式会社 | Ophthalmic aqueous composition |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
-
2012
- 2012-02-23 EP EP12156652.5A patent/EP2630952A1/en not_active Withdrawn
-
2013
- 2013-02-22 EA EA201400869A patent/EA201400869A1/en unknown
- 2013-02-22 KR KR1020147026658A patent/KR20140124405A/en active Search and Examination
- 2013-02-22 WO PCT/EP2013/053556 patent/WO2013124415A1/en active Application Filing
- 2013-02-22 MX MX2014010005A patent/MX2014010005A/en unknown
- 2013-02-22 US US14/380,655 patent/US9682147B2/en not_active Expired - Fee Related
- 2013-02-22 EP EP13707332.6A patent/EP2816998A1/en not_active Withdrawn
- 2013-02-22 CA CA2862932A patent/CA2862932A1/en not_active Abandoned
- 2013-02-22 NZ NZ627861A patent/NZ627861A/en not_active IP Right Cessation
- 2013-02-22 JP JP2014558119A patent/JP6231499B2/en active Active
- 2013-02-22 AU AU2013224043A patent/AU2013224043B2/en not_active Ceased
- 2013-02-22 CN CN201380009668.6A patent/CN104220048A/en active Pending
- 2013-02-22 UA UAA201408067A patent/UA112669C2/en unknown
- 2013-02-22 SG SG11201405098PA patent/SG11201405098PA/en unknown
- 2013-02-22 MY MYPI2014002437A patent/MY169504A/en unknown
- 2013-02-22 TW TW102106150A patent/TWI564032B/en not_active IP Right Cessation
- 2013-02-22 IN IN6853DEN2014 patent/IN2014DN06853A/en unknown
-
2014
- 2014-08-22 PH PH12014501906A patent/PH12014501906A1/en unknown
-
2015
- 2015-04-16 HK HK15103727.7A patent/HK1203154A1/en unknown
- 2015-04-16 HK HK15103726.8A patent/HK1203153A1/en unknown
-
2017
- 2017-10-19 JP JP2017202485A patent/JP2018039828A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015509494A (en) | 2015-03-30 |
| EP2816998A1 (en) | 2014-12-31 |
| TW201347786A (en) | 2013-12-01 |
| MX2014010005A (en) | 2015-03-09 |
| CA2862932A1 (en) | 2013-08-29 |
| AU2013224043B2 (en) | 2017-07-27 |
| MY169504A (en) | 2019-04-15 |
| PH12014501906A1 (en) | 2014-11-24 |
| NZ627861A (en) | 2016-02-26 |
| EA201400869A1 (en) | 2014-12-30 |
| HK1203153A1 (en) | 2015-10-23 |
| TWI564032B (en) | 2017-01-01 |
| KR20140124405A (en) | 2014-10-24 |
| UA112669C2 (en) | 2016-10-10 |
| WO2013124415A1 (en) | 2013-08-29 |
| CN104220048A (en) | 2014-12-17 |
| JP2018039828A (en) | 2018-03-15 |
| IN2014DN06853A (en) | 2015-05-22 |
| AU2013224043A1 (en) | 2014-08-21 |
| JP6231499B2 (en) | 2017-11-15 |
| EP2630952A1 (en) | 2013-08-28 |
| US9682147B2 (en) | 2017-06-20 |
| HK1203154A1 (en) | 2015-10-23 |
| US20150025020A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1203153A1 (en) | Self-preserved oil dispersions comprising boric | |
| ZA201407555B (en) | Tailored oils | |
| HK1209332A1 (en) | Apoptosis-inducing agents | |
| EP2891703A4 (en) | Lubricant composition | |
| EP2826847A4 (en) | Lubricating oil composition | |
| EP2835534A4 (en) | Oil separator | |
| EP2821604A4 (en) | Oil separator | |
| EP2826846A4 (en) | Lubricant composition | |
| EP2821605A4 (en) | Oil separator | |
| SG11201404647QA (en) | Lubricant composition | |
| EP2878655A4 (en) | Engine oil composition | |
| EP2906504A4 (en) | Watewater refinery | |
| EP2878659A4 (en) | Lubricating oil composition | |
| EP2754862A4 (en) | Oil jet | |
| EP2832832A4 (en) | Lubricating oil composition | |
| EP2832830A4 (en) | Lubricating oil composition | |
| EP2832839A4 (en) | Lubricating oil composition | |
| EP2868740A4 (en) | Lubricant composition | |
| EP2832228A4 (en) | Oil/fat composition | |
| EP2886631A4 (en) | Lubricating oil composition | |
| EP2878658A4 (en) | Lubricating oil composition | |
| EP2837676A4 (en) | Lubricant composition | |
| EP2837677A4 (en) | Lubricating oil composition | |
| EP2873718A4 (en) | Lubricating oil composition | |
| EP2818541A4 (en) | Isolator |